股市必读：京新药业（002020）11月7日董秘有最新回复

Core Viewpoint - The company Jingxin Pharmaceutical (002020) is currently facing market fluctuations, with its stock price at 18.02 yuan, down 0.72% as of November 7, 2025, indicating a short-term trading characteristic in the market [1]. Group 1: Company Developments - The company has submitted an application for the approval of its drug, Calcium Chloride, which is expected to enter the National Medical Insurance Directory upon approval [2]. - The company is actively promoting its two major products, Didasyn and Calcium Chloride, which are projected to reach peak sales of several billion yuan in the next 2-3 years [2]. - The sales efforts for Didasyn are ongoing, with the company focusing on hospital admissions and academic promotion activities to enhance patient accessibility [2]. Group 2: Market Activity - On November 7, the net outflow of main funds was 6.74 million yuan, while the net inflow of speculative funds was 10.57 million yuan, indicating a clear short-term speculative trading pattern in the market [2]. - Retail investors experienced a net outflow of 3.82 million yuan on the same day, reflecting a cautious sentiment among smaller investors [2].